uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08 2023 - 7:05AM
uniQure Announces Inducement Grants Under Nasdaq Listing Rule
5635(c)(4)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced the grant of inducement equity awards to
newly hired employees.
The company granted equity awards to 28
employees as a material inducement to commencing their employment.
In the aggregate, those employees received 142,300 restricted share
units and options to purchase 52,500 ordinary shares of the
company. Each option has an exercise price of $7.30 per share, the
closing price per ordinary share as reported by Nasdaq on the grant
date. Each option has a ten-year term and will vest over four
years, with 25% of the original number of shares vesting on the
first anniversary of the grant date and an additional 6.25% of the
shares vesting in approximately equal quarterly installments over
the twelve successive quarters thereafter. The restricted share
units vest in three approximately equal annual installments
beginning on December 7, 2024.
The aforementioned equity awards were approved
by the company’s board of directors on December 7, 2023 and were
issued to newly hired employees as a material inducement to
commencing their employment with the company in accordance with and
under Nasdaq Listing Rule 5635(c)(4).
About uniQure
uniQure’s mission is to reimagine the future of
medicine by delivering innovative cures that transform lives. The
recent approvals of our gene therapy for hemophilia B – a historic
achievement based on more than a decade of research and clinical
development – represents a major milestone in the field of genomic
medicine and ushers in a new treatment approach for patients living
with hemophilia. We are now leveraging our modular and validated
technology and manufacturing platform to advance a pipeline of
proprietary gene therapies for the treatment of patients with
Huntington's disease, refractory mesial temporal lobe epilepsy,
amyotrophic lateral sclerosis (ALS), Fabry disease, and other
severe diseases. www.uniQure.com
uniQure Contacts: |
|
|
|
FOR INVESTORS: |
FOR MEDIA: |
|
|
Chiara Russo |
Tom Malone |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
Mobile: 617-306-9137 |
Mobile:339-223-8541 |
c.russo@uniQure.com |
t.malone@uniQure.com |
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Jul 2024 to Aug 2024
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Aug 2023 to Aug 2024